3-Amino-4-(3-methylbutylamino)benzoic acid | 869578-55-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-Amino-4-(3-methylbutylamino)benzoic acid
• CAS: 869578-55-2
• 化学式: C₁₂H₁₈N₂O₂
• 分子量: 222.287
• InChiKey: OZVVPFFNEXFZHU-UHFFFAOYSA-N

物化性质

• 沸点：
  409.2±40.0 °C(Predicted)
• 密度：
  1.169±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  16
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  75.4
• 氢给体数：
  3
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  3-Amino-4-(3-methylbutylamino)benzoic acid 在 palladium on activated charcoal 、 氢气 、 对甲苯磺酸 作用下， 以 溶剂黄146 为溶剂， 20.0~155.0 ℃ 、800.01 kPa 条件下， 反应 0.17h， 生成 methyl 1-isopentyl-1H-benzo[d]imidazole-5-carboxylate
  参考文献：
  名称：

  Design and synthesis of conformationally restricted inhibitors of active thrombin activatable fibrinolysis inhibitor (TAFIa)

  摘要：

  A series of 4,5,6,7-tetrahydro-1H-benzimidazole-5-carboxylic acid and 5,6,7,8-tetrahydroimidazo [1,2-a] pyridine-7-carboxylic acid derivatives designed as inhibitors of TAFIa has been prepared via a common hydrogenation-alkylation sequence starting from the appropriate benzimidazole and imidazopyridine system. We present a successful design strategy using a conformational restriction approach resulting in potent and selective inhibitors of TAFIa. The X-ray structure of compound 5 in complex with a H333Y/H335Q double mutant TAFI indicate that the conformational restriction is responsible for the observed potency increase. (c) 2014 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2014.02.010
• 作为产物：
  描述：

  4-氟-3-硝基苯甲酸 在 硫酸 作用下， 以 甲醇 为溶剂， 生成 3-Amino-4-(3-methylbutylamino)benzoic acid
  参考文献：
  名称：

  Design and synthesis of conformationally restricted inhibitors of active thrombin activatable fibrinolysis inhibitor (TAFIa)

  摘要：

  A series of 4,5,6,7-tetrahydro-1H-benzimidazole-5-carboxylic acid and 5,6,7,8-tetrahydroimidazo [1,2-a] pyridine-7-carboxylic acid derivatives designed as inhibitors of TAFIa has been prepared via a common hydrogenation-alkylation sequence starting from the appropriate benzimidazole and imidazopyridine system. We present a successful design strategy using a conformational restriction approach resulting in potent and selective inhibitors of TAFIa. The X-ray structure of compound 5 in complex with a H333Y/H335Q double mutant TAFI indicate that the conformational restriction is responsible for the observed potency increase. (c) 2014 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2014.02.010

文献信息

• Design and synthesis of conformationally restricted inhibitors of active thrombin activatable fibrinolysis inhibitor (TAFIa)
  作者：Mikael Brink、Anders Dahlén、Thomas Olsson、Magnus Polla、Tor Svensson

  DOI：10.1016/j.bmc.2014.02.010

  日期：2014.4

  A series of 4,5,6,7-tetrahydro-1H-benzimidazole-5-carboxylic acid and 5,6,7,8-tetrahydroimidazo [1,2-a] pyridine-7-carboxylic acid derivatives designed as inhibitors of TAFIa has been prepared via a common hydrogenation-alkylation sequence starting from the appropriate benzimidazole and imidazopyridine system. We present a successful design strategy using a conformational restriction approach resulting in potent and selective inhibitors of TAFIa. The X-ray structure of compound 5 in complex with a H333Y/H335Q double mutant TAFI indicate that the conformational restriction is responsible for the observed potency increase. (c) 2014 Elsevier Ltd. All rights reserved.